Probiotic findings weaken when analysis focuses on lower-bias trials
A pooled improvement in a pancreatic-function marker was not confirmed in the lower-bias trials, leaving uncertainty about the underlying benefit.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Across all trials, probiotics improved HOMA-β, a model-based marker of pancreatic beta-cell function. However, restricting the analysis to trials judged at low risk of bias produced no statistically significant effect. This weakens confidence in the overall finding and does not establish benefits for symptoms, diabetes complications or long-term health.
Results varied substantially across trials. The abstract does not report treatment durations or enough formulation details to connect the pooled estimates to a particular probiotic product.
What researchers found
HOMA-β, all included trials
Probiotics versus controls; mean difference in the marker, with assessment timing not reported.
HOMA-β, trials at low risk of bias
Probiotics versus controls; mean difference was not statistically significant. Assessment timing was not reported.
A marker outcome
HOMA-β was the measured endpoint, so the result concerns an estimated aspect of pancreatic function. A shift in that marker alone does not demonstrate a meaningful improvement in everyday health.
Uncertainty remains
The estimate from trials at low risk of bias was compatible with changes in either direction. A nonsignificant result leaves uncertainty; it does not prove that probiotics have no effect.
The original publication
Effects of probiotic supplementation on islet β-cell function in subjects with glucose metabolism disorders: a meta-analysis.
Xiang M, Sa X, Tuo Z et al.
Front Nutr · 2025
- PubMed ID
- 41112739
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.